Pediatrix Medical Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Pediatrix Medical Group han disminuido a una tasa media anual de -14.5%, mientras que en la industria Healthcare los beneficios crecieron en un 4.4% anualmente. Los ingresos han ido disminuyendo a una tasa media de 2.6% al año.

Información clave

-20.6%

Tasa de crecimiento de los beneficios

-19.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	15.7%
Tasa de crecimiento de los ingresos	-3.2%
Rentabilidad financiera	-8.2%
Margen neto	-3.5%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Pediatrix Medical Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:PDC Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	1,999	-71	229
31 Dec 23	1,995	-60	228
30 Sep 23	2,012	88	226
30 Jun 23	1,995	95	226
31 Mar 23	1,981	98	229
31 Dec 22	1,972	63	231
30 Sep 22	1,957	79	239
30 Jun 22	1,960	82	248
31 Mar 22	1,947	82	258
31 Dec 21	1,911	108	263
30 Sep 21	1,829	72	259
30 Jun 21	1,797	38	259
31 Mar 21	1,739	14	248
31 Dec 20	1,734	-10	249
30 Sep 20	1,776	-4	253
30 Jun 20	1,770	11	250
31 Mar 20	1,678	1	230
31 Dec 19	1,780	42	245
30 Sep 19	2,210	94	291
30 Jun 19	2,603	143	323
31 Mar 19	3,145	221	384
31 Dec 18	1,723	122	232
30 Sep 18	3,477	333	450
30 Jun 18	3,497	337	456
31 Mar 18	3,475	326	458
31 Dec 17	3,253	305	386
30 Sep 17	3,378	262	443
30 Jun 17	3,337	293	435
31 Mar 17	3,266	312	424
31 Dec 16	3,183	325	411
30 Sep 16	3,094	340	393
30 Jun 16	2,988	334	379
31 Mar 16	2,893	336	360
31 Dec 15	2,780	336	338
30 Sep 15	2,689	332	316
30 Jun 15	2,593	327	296
31 Mar 15	2,512	322	285
31 Dec 14	2,439	317	275
30 Sep 14	2,356	308	262
30 Jun 14	2,284	299	256
31 Mar 14	2,218	289	250
31 Dec 13	2,154	281	245
30 Sep 13	2,058	268	237
30 Jun 13	1,976	257	230

Ingresos de calidad: PDC actualmente no es rentable.

Margen de beneficios creciente: PDC actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: PDC no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 14.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de PDC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: PDC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (-7.5%).

Rentabilidad financiera

Alta ROE: PDC tiene una rentabilidad financiera negativa (-7.11%), ya que actualmente no es rentable.

Pediatrix Medical Group Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.17 in 1Q 2023)

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: US$0.73 loss per share (vs US$0.75 profit in FY 2022)

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.35 in 3Q 2022)

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.17 in 1Q 2023)

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings released: US$0.73 loss per share (vs US$0.75 profit in FY 2022)

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.35 in 3Q 2022)

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 2Q 2022)

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings released: EPS: US$0.17 (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$750 (vs US$1.27 in FY 2021)

Pediatrix Medical Group, Inc. Announces Executive Changes

CEO & Director recently sold €334k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold €368k worth of stock

Third quarter 2022 earnings released: EPS: US$0.35 (vs US$0.37 in 3Q 2021)

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix Medical Group, Inc. Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.36 in 2Q 2021)

Pediatrix Medical Group, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Mednax Announces Leadership Appointments

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.063 profit in 1Q 2021)

High number of new directors

MEDNAX, Inc. to Report Q1, 2022 Results on Apr 28, 2022

MEDNAX, Inc., Annual General Meeting, May 12, 2022

MEDNAX, Inc. Announces Resignation of Roger Mack Hinson as President of Pediatrix and Obstetrix Medical Group, Effective as of June 1, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MEDNAX, Inc. Provides Earnings Guidance for the Year 2022

MEDNAX, Inc. to Report Q4, 2021 Results on Feb 17, 2022

MEDNAX, Inc. (NYSE:MD) acquired Night Lite Pediatrics.

Senior VP & Chief Accounting Officer recently sold €215k worth of stock

Third quarter 2021 earnings released: EPS US$0.37 (vs US$0.032 loss in 3Q 2020)

Senior VP & Chief Accounting Officer recently sold €268k worth of stock

Second quarter 2021 earnings released: EPS US$0.36 (vs US$0.085 in 2Q 2020)

New 90-day high: €23.60

Full year 2020 earnings released: US$0.12 loss per share (vs US$13.77 loss in FY 2019)

Revenue misses expectations

MEDNAX, Inc. to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €20.00

Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group

New 90-day high: €19.60

New 90-day high: €17.20

New 90-day high: €16.60

Revenue misses expectations

Third quarter 2020 earnings released: US$0.032 loss per share

New 90-day low: €12.80

New 90-day low: €14.10

Executive VP recently sold €352k worth of stock

New 90-day high - €17.30

MEDNAX, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MEDNAX, Inc. Announces Executive Change

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Dynamic Index

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Index

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta